THREAD Advances Complex Study Designs with the Next Adaptive Clinical Trials Now Enrolling

Since launching its Adaptive Trial solution, THREAD has helped design several new adaptive studies using the platform's new configurable workflows

CARY, N.C., 30 SEP 2026 – THREAD, a leading no-code clinical research technology platform with scientific consulting for decentralized clinical trials (DCT) and electronic clinical outcome assessments (eCOA), today announced that biopharmaceutical sponsors and CROs have already designed several global adaptive clinical trials using the companies recently launched Adaptive Trials Solution. The milestone highlights growing industry demand for configurable technology and enablement services to simplify the operational complexity of modern clinical trial designs while speeding up study launch timelines.

Building on the launch of its Adaptive Trials Solution earlier this year, THREAD's configurable platform enables sponsors to operationalize basket, umbrella, multi-arm, and other adaptive study designs within a single protocol. Since the feature's release, sponsors have leveraged the platform to rapidly configure complex participant pathways, cohort management, protocol adaptations, and study governance without custom development on global Phase Ib – IV clinical trials and registries.

The adoption aligns with recent regulations that continue to encourage more efficient approaches to evidence generation. Recent FDA initiatives supporting the use of well-designed single pivotal trials, alongside expanded guidance for adaptive clinical trial designs, are creating new opportunities for sponsors to accelerate development while maintaining rigorous scientific standards. Adaptive trials allow sponsors to make pre-specified modifications based on interim data that help optimize patient enrollment, allocate resources more effectively, and potentially reach pivotal endpoints with greater efficiency when appropriately planned.

THREAD's Adaptive Trials Solution provides research teams with configurable workflows that support:

• Dynamic participant pathways across multiple cohorts and treatment arms
• Rapid implementation of protocol adaptations
• Role-based governance for participant transitions
• Automated visit and task management that maintains a seamless participant experience
• A single study configuration capable of supporting evolving trial designs

"We're seeing a meaningful shift in how sponsors think about pivotal trial design and the volume of adaptive study designs we are receiving," said John Reites, Co-founder and CEO of THREAD. "We are grateful for the opportunity to support our clients with these new adaptive clinical trials to demonstrate how our platform and scientific consulting deliver the results they need in a partner.”

To learn more about THREAD's Adaptive Trials Solution or schedule a demonstration, visit https://www.threadresearch.com/adaptive-trial

##

About THREAD

THREAD’s® purpose is to leverage its clinical research platform to enable studies for everyone, everywhere. Through its uniquely combined research technology and scientific consulting services, THREAD helps life science organizations to design, operate, and scale next-generation research studies and electronic clinical outcome assessments (eCOA) programs for participants, sites, and study teams. Through its comprehensive platform and scientific expertise, THREAD empowers studies to be accessible, efficient, and human-centered.

THREAD has been recognized as a leader by Everest Group in its Decentralized Clinical Trial Product PEAK Matrix® Assessments from 2021 through 2023, is positioned in the Leaders Category of the 2022 IDC MarketScape for R&D Decentralized Clinical Trial Technology Solutions Vendor Assessment, and is named a Major Contender in Everest Group’s Life Sciences eCOA Products PEAK Matrix® Assessment 2025.

Media Contact

Les Yates
THREAD
media@THREADresearch.com